Cadonilimab plus chemotherapy fails cost-effectiveness test for advanced gastric cancer in China
A model-based analysis found that adding cadonilimab to first-line chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma gained 0.25 ...










